Summary:
The company, based in Singapore, specialises in the development and deployment of AI deep learning systems in the healthcare industry. The company has developed an automated system that is able to detect 3 retina diseases concurrently. Through analysis of digital colour retina images, the system is able to identify signs of diabetic retinopathy, glaucoma and age-related-macular degeneration.
Description:
With an exploding diabetic population in the world and the need for every diabetic patient to have their eyes screened at least once a year, the product is the solution to mass screen populations for the detection of diabetic retinopathy. Diabetic retinopathy affects 1 in 3 diabetics and 1 in 10 loses their vision because of this debilitating disease.
Early detection and intervention play a paramount role in the treatment of this condition. For resource-limited countries, where there are a limited number of human graders, the product can reduce the burden of screening exercises within an institution or country. The product can help ophthalmologists sieve through patients who need the treatment most.
The product can concurrently detect glaucoma and age related macular degeneration. The product is Singapore HSA approved and has recently attained CE Mark. The company is EN ISO13485:2016 accredited.
The company is actively looking for partners in Europe via distribution service agreement. Subject to discussion, the company is also open to other forms of collaborative efforts.
Type (e.g. company, R&D institution…), field of industry and Role of Partner Sought:
The company is looking for partners in the medical technology industry with good connections to hospitals and healthcare institutions across European cities. Preferably, partner should also be distributing medical technology products.
The partnership is achieved through distribution service agreement.
Stage of Development:
Already on the market
External code:
BOSG20200417001
